Among the most popular fund investment industries, there are Manufacturing, Health Care. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Silk Therapeutics.
The high activity for fund was in 2016. The usual things for fund are deals in the range of 5 - 10 millions dollars. The fund is constantly included in less than 2 investment rounds annually.
The usual cause for the fund is to invest in rounds with 5 partakers. Despite the Aultman Health Foundation, startups are often financed by The Kraft Group. The meaningful sponsors for the fund in investment in the same round are The Kraft Group, Richard Sackler, Lear Corporation. In the next rounds fund is usually obtained by The Kraft Group, Roy P. Disney, Roy P.
|Beyond Standard||Japan, Tokyo|
|Dachen Chuanglian||China, Guangdong, Shenzhen|
|Dineout||India, Noida, Uttar Pradesh|
|Frontier Angel Fund||Montana, Polson, United States|
|Partners Group||Baar, Switzerland, Zug|
|Plug and Play FinTech||California, Sunnyvale, United States|
|RBV Capital||Moscow, Moscow, Russia|
|TUI Group||Germany, Hanover, Niedersachsen|
|Xiamen University Asset Management Company Limited||China, Fujian, Xiamen|
|$6M||03 Feb 2016||Massachusetts, United States|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.